Evidence map›Paper›PMID 36359365›Full record

ArticleBiomedicines2022

Urinary Cysteinyl Leukotrienes as Biomarkers of Endothelial Activation, Inflammation and Oxidative Stress and Their Relationship with Organ Dysfunction in Human Septic Shock.

Marta Reina-Couto, Marisa Santos-Oliveira, Patrícia Pereira-Terra, Carolina Silva-Pereira, Janete Quelhas-Santos, Álvaro Duarte, Sandra Martins, Paula Serrão, Cláudia Camila Dias, Manuela Morato and 5 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Marta Reina-CoutoDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.
Marisa Santos-OliveiraDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.
Patrícia Pereira-TerraDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.
Carolina Silva-PereiraDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.
Janete Quelhas-SantosDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.
Álvaro DuarteDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.
Sandra MartinsServiço de Patologia Clínica, Centro Hospitalar Universitário São João, 4200-319 Porto, Portugal.ORCID 0000-0001-6813-314X
Paula SerrãoDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.
Cláudia Camila DiasDepartamento de Medicina da Comunidade, Informação e Decisão em Saúde, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.ORCID 0000-0001-9356-3272
Manuela MoratoLaboratório de Farmacologia, Departamento de Ciências do Medicamento, Faculdade de Farmácia da Universidade do Porto, 4050-313 Porto, Portugal.ORCID 0000-0002-9509-0613
João T GuimarãesServiço de Patologia Clínica, Centro Hospitalar Universitário São João, 4200-319 Porto, Portugal.ORCID 0000-0003-4836-6311
Roberto Roncon-AlbuquerqueServiço de Medicina Intensiva, Centro Hospitalar Universitário São João, 4200-319 Porto, Portugal.
José-Artur PaivaServiço de Medicina Intensiva, Centro Hospitalar Universitário São João, 4200-319 Porto, Portugal.
António Albino-TeixeiraDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.
Teresa SousaDepartamento de Biomedicina-Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.ORCID 0000-0001-7230-5020
Universidade do Porto · PT

Funding

FEDER/COMPETE/Portugal 2020 - Operational Programme for Competitiveness and Internationalization (POCI) & Portuguese Foundation for Science and Technology (FCT) POCI-01-0145-FEDER-032188 & PTDC/MEC-CAR/32188/2017)
6 · The paper itself

Abstract

Cysteinyl leukotrienes (CysLT) are potent vascular leakage-promoting agents but have been scarcely explored in human septic shock (SS). We evaluated CysLT at admission and during hospitalization and their correlation with endothelial dysfunction, inflammation, oxidative stress, the renin-angiotensin-aldosterone system, and cardiac, renal, respiratory, and hepatic parameters in SS patients. Blood and spot-urine samples were collected at days 1-2 (admission), 3-4, and 5-8 in SS patients (n = 13) and at a single time point in controls (n = 22). Urinary CysLT (u-CysLT) and isoprostanes, plasma, and urinary angiotensinogen, serum myeloperoxidase, and IL-10 were quantified by ELISA. Serum intercellular-adhesion molecule-1, vascular cell-adhesion molecule-1, E-selectin, tumor necrosis factor-α, IL-1β, and IL-6 were measured by multiplex immunoassays. Routine markers were evaluated using automated analyzers. At admission, SS patients had increased u-CysLT, endothelial activation, inflammation, oxidative stress, and plasma and urinary angiotensinogen, as well as cardiac, respiratory, hepatic, and renal injury/dysfunction. There were no changes in u-CysLT during hospitalization. Both correlation and multivariate analyses showed positive relationships of u-CysLT with endothelial activation, inflammation, oxidative stress, proteinuria, and hepatic injury/dysfunction markers. These results suggest that u-CysLT may be potential non-invasive biomarkers for monitoring the pathophysiological mechanisms underlying SS, as well as putative therapeutic targets.

Indexed as

cysteinyl leukotrienesendothelial activationinflammationorgan dysfunctionoxidative stressseptic shock

Identifiers

PMID36359365
PMCPMC9687332
OpenAlexW4308531269

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.